{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:20:59Z","timestamp":1780413659244,"version":"3.54.1"},"reference-count":192,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1038\/s41585-019-0233-z","type":"journal-article","created":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T11:10:59Z","timestamp":1570705859000},"page":"655-673","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Drug resistance in papillary RCC: from putative mechanisms to clinical practicalities"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0017-1040","authenticated-orcid":false,"given":"Anna","family":"Brodziak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4103-1626","authenticated-orcid":false,"given":"Pawe\u0142","family":"Sobczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Bartnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-3608","authenticated-orcid":false,"given":"Micha\u0142","family":"Fiedorowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cezary","family":"Szczylik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2107-3810","authenticated-orcid":false,"given":"Anna M.","family":"Czarnecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,10]]},"reference":[{"key":"233_CR1","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1101\/gr.131110.111","volume":"22","author":"WM Linehan","year":"2012","unstructured":"Linehan, W. M. Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics. Genome Res. 22, 2089\u20132100 (2012).","journal-title":"Genome Res."},{"key":"233_CR2","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nrurol.2010.47","volume":"7","author":"WM Linehan","year":"2010","unstructured":"Linehan, W. M., Srinivasan, R. & Schmidt, L. S. The genetic basis of kidney cancer: a metabolic disease. Nat. Rev. Urol. 7, 277\u2013285 (2010).","journal-title":"Nat. Rev. Urol."},{"key":"233_CR3","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1200\/JCO.2005.07.055","volume":"23","author":"JJ Patard","year":"2005","unstructured":"Patard, J. J. et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J. Clin. Oncol. 23, 2763\u20132771 (2005).","journal-title":"J. Clin. Oncol."},{"key":"233_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","volume":"70","author":"H Moch","year":"2016","unstructured":"Moch, H., Cubilla, A. L., Humphrey, P. A., Reuter, V. E. & Ulbright, T. M. The 2016 WHO Classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur. Urol. 70, 93\u2013105 (2016).","journal-title":"Eur. Urol."},{"key":"233_CR5","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/01.cji.0000170357.14962.9b","volume":"28","author":"MP Upton","year":"2005","unstructured":"Upton, M. P., Parker, R. A., Youmans, A., McDermott, D. F. & Atkins, M. B. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J. Immunother. 28, 488\u2013495 (2005).","journal-title":"J. Immunother."},{"key":"233_CR6","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1056\/NEJM199609193351207","volume":"335","author":"RJ Motzer","year":"1996","unstructured":"Motzer, R. J., Bander, N. H. & Nanus, D. M. Renal-cell carcinoma. N. Engl. J. Med. 335, 865\u2013875 (1996).","journal-title":"N. Engl. J. Med."},{"key":"233_CR7","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/00000478-200203000-00001","volume":"26","author":"MB Amin","year":"2002","unstructured":"Amin, M. B. et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am. J. Surg. Pathol. 26, 281\u2013291 (2002).","journal-title":"Am. J. Surg. Pathol."},{"key":"233_CR8","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1016\/j.ejca.2012.05.002","volume":"48","author":"S Steffens","year":"2012","unstructured":"Steffens, S. et al. Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma \u2014 a multicentre study. Eur. J. Cancer 48, 2347\u20132352 (2012).","journal-title":"Eur. J. Cancer"},{"key":"233_CR9","first-page":"423908","volume":"2015,","author":"H Liddell","year":"2015","unstructured":"Liddell, H., Mare, A., Heywood, S., Bennett, G. & Chan, H. F. Clear cell papillary renal cell carcinoma: a potential mimic of conventional clear cell renal carcinoma on core biopsy. Case Rep. Urol. 2015, 423908 (2015).","journal-title":"Case Rep. Urol."},{"key":"233_CR10","first-page":"537","volume":"10","author":"B Delahunt","year":"1997","unstructured":"Delahunt, B. & Eble, J. N. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod. Pathol. 10, 537\u2013544 (1997).","journal-title":"Mod. Pathol."},{"key":"233_CR11","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S0022-5347(17)35015-2","volume":"151","author":"B Zbar","year":"1994","unstructured":"Zbar, B. et al. Hereditary papillary renal cell carcinoma. J. Urol. 151, 561\u2013566 (1994).","journal-title":"J. Urol."},{"key":"233_CR12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1056\/NEJMoa1505917","volume":"374","author":"Cancer Genome Atlas Research Network","year":"2016","unstructured":"Cancer Genome Atlas Research Network. et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N. Engl. J. Med. 374, 135\u2013145 (2016).","journal-title":"N. Engl. J. Med."},{"key":"233_CR13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.eururo.2017.05.033","volume":"73","author":"SK Pal","year":"2018","unstructured":"Pal, S. K. et al. Characterization of clinical cases of advanced papillary renal cell carcinoma via comprehensive genomic profiling. Eur. Urol. 73, 71\u201378 (2018).","journal-title":"Eur. Urol."},{"key":"233_CR14","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1200\/JCO.2002.11.123","volume":"20","author":"RJ Motzer","year":"2002","unstructured":"Motzer, R. J. et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J. Clin. Oncol. 20, 2376\u20132381 (2002).","journal-title":"J. Clin. Oncol."},{"key":"233_CR15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer, R. J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115\u2013124 (2007).","journal-title":"N Engl. J. Med."},{"key":"233_CR16","doi-asserted-by":"publisher","first-page":"v58","DOI":"10.1093\/annonc\/mdw328","volume":"27","author":"B Escudier","year":"2016","unstructured":"Escudier, B. et al. Renal cell carcinoma: esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 27, v58\u2013v68 (2016).","journal-title":"Ann. Oncol."},{"key":"233_CR17","doi-asserted-by":"publisher","first-page":"804","DOI":"10.6004\/jnccn.2017.0100","volume":"15","author":"RJ Motzer","year":"2017","unstructured":"Motzer, R. J. et al. Kidney Cancer, Version 2.2017, NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 15, 804\u2013834 (2017).","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"233_CR18","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/annonc\/mdz056","volume":"30","author":"B Escudier","year":"2019","unstructured":"Escudier, B. et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 30, 706\u2013720 (2019).","journal-title":"Ann. Oncol."},{"key":"233_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-016-0565-8","volume":"15","author":"KK Brodaczewska","year":"2016","unstructured":"Brodaczewska, K. K., Szczylik, C., Fiedorowicz, M., Porta, C. & Czarnecka, A. M. Choosing the right cell line for renal cell cancer research. Mol. Cancer 15, 83 (2016).","journal-title":"Mol. Cancer"},{"key":"233_CR20","volume":"191","author":"AA Hakimi","year":"2014","unstructured":"Hakimi, A. A., Chevinsky, M., Hsieh, J. J., Sander, C. & Sinha, R. MP23-11 Genomic comparison of renal cell carcinoma cell lines to human tumORS. J. Urol. 191, e247 (2014).","journal-title":"J. Urol."},{"key":"233_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15165","volume":"8","author":"R Sinha","year":"2017","unstructured":"Sinha, R. et al. Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection. Nat. Commun. 8, 15165 (2017).","journal-title":"Nat. Commun."},{"key":"233_CR22","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1158\/0008-5472.CAN-06-4571","volume":"67","author":"KA Furge","year":"2007","unstructured":"Furge, K. A. et al. Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. Cancer Res. 67, 3171\u20133176 (2007).","journal-title":"Cancer Res."},{"key":"233_CR23","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1073\/pnas.1012500108","volume":"108","author":"BD Looyenga","year":"2011","unstructured":"Looyenga, B. D. et al. Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas. Proc. Natl Acad. Sci. USA 108, 1439\u20131444 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"233_CR24","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/sj.cgt.7700342","volume":"8","author":"KJ Pulkkanen","year":"2001","unstructured":"Pulkkanen, K. J. et al. HSV-tk gene therapy for human renal cell carcinoma in nude mice. Cancer Gene Ther. 8, 529\u2013536 (2001).","journal-title":"Cancer Gene Ther."},{"key":"233_CR25","first-page":"348","volume":"52","author":"P Anglard","year":"1992","unstructured":"Anglard, P. et al. Molecular and cellular characterization of human renal cell carcinoma cell lines. Cancer Res. 52, 348\u2013356 (1992).","journal-title":"Cancer Res."},{"key":"233_CR26","doi-asserted-by":"publisher","first-page":"6861","DOI":"10.1038\/sj.onc.1208841","volume":"24","author":"C Yu","year":"2005","unstructured":"Yu, C. et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 24, 6861\u20136869 (2005).","journal-title":"Oncogene"},{"key":"233_CR27","unstructured":"Bairlein, M. Characterization of the small molecule kinase inhibitor SU11248 (Sunitinib\/SUTENT) in vitro and in vivo \u2013 Towards response prediction in cancer therapy with kinase inhibitors. Thesis, Technische Univ. M\u00fcnchen (2010)."},{"key":"233_CR28","doi-asserted-by":"publisher","first-page":"20150163","DOI":"10.1259\/bjr.20150163","volume":"88","author":"TY Jeon","year":"2015","unstructured":"Jeon, T. Y. et al. Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging. Br. J. Radiol. 88, 20150163 (2015).","journal-title":"Br. J. Radiol."},{"key":"233_CR29","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2220\/biomedres.29.271","volume":"29","author":"S Tochizawa","year":"2008","unstructured":"Tochizawa, S. et al. Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines. Biomed. Res. 29, 271\u2013278 (2008).","journal-title":"Biomed. Res."},{"key":"233_CR30","first-page":"4532","volume":"54","author":"M Korhonen","year":"1994","unstructured":"Korhonen, M., Sariola, H., Gould, V. E., Kangas, L. & Virtanen, I. Integrins and laminins in human renal carcinoma cells and tumors grown in nude mice. Cancer Res. 54, 4532\u20134538 (1994).","journal-title":"Cancer Res."},{"key":"233_CR31","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.cll.2005.01.007","volume":"25","author":"B Delahunt","year":"2005","unstructured":"Delahunt, B. & Eble, J. N. History of the development of the classification of renal cell neoplasia. Clin. Lab. Med. 25, 231\u2013246, v (2005).","journal-title":"Clin. Lab. Med."},{"key":"233_CR32","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/carcin\/bgl143","volume":"28","author":"T Shinojima","year":"2007","unstructured":"Shinojima, T. et al. Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha. Carcinogenesis 28, 529\u2013536 (2007).","journal-title":"Carcinogenesis"},{"key":"233_CR33","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1038\/sj.onc.1202547","volume":"18","author":"L Schmidt","year":"1999","unstructured":"Schmidt, L. et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 18, 2343\u20132350 (1999).","journal-title":"Oncogene"},{"key":"233_CR34","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/ng0597-68","volume":"16","author":"L Schmidt","year":"1997","unstructured":"Schmidt, L. et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. 16, 68\u201373 (1997).","journal-title":"Nat. Genet."},{"key":"233_CR35","first-page":"11","volume":"1","author":"I de Aguirre","year":"2006","unstructured":"de Aguirre, I. et al. c-Met mutational analysis in the Sema and juxtamembrane domains in small-cell-lung-cancer. Transl Oncogenomics 1, 11\u201318 (2006).","journal-title":"Transl Oncogenomics"},{"key":"233_CR36","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/gcc.2870030403","volume":"3","author":"G Kovacs","year":"1991","unstructured":"Kovacs, G., Fuzesi, L., Emanual, A. & Kung, H. F. Cytogenetics of papillary renal cell tumors. Genes Chromosomes Cancer 3, 249\u2013255 (1991).","journal-title":"Genes Chromosomes Cancer"},{"key":"233_CR37","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/j.1349-7006.2000.tb00927.x","volume":"91","author":"Z-Q Yang","year":"2000","unstructured":"Yang, Z.-Q. et al. Molecular cytogenetic analysis of 17 renal cancer cell lines: increased copy number at 5q31-33 in cell lines from nonpapillary carcinomas. Jpn J. Cancer Res. 91, 156\u2013163 (2000).","journal-title":"Japanese J. Cancer Res."},{"key":"233_CR38","doi-asserted-by":"publisher","first-page":"20448","DOI":"10.1074\/jbc.M114.580597","volume":"289","author":"YH Lee","year":"2014","unstructured":"Lee, Y. H., Morrison, B. L. & Bottaro, D. P. Synergistic signaling of tumor cell invasiveness by hepatocyte growth factor and hypoxia. J. Biol. Chem. 289, 20448\u201320461 (2014).","journal-title":"J. Biol. Chem."},{"key":"233_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-39305-z","volume":"9","author":"TC Peak","year":"2019","unstructured":"Peak, T. C., Su, Y., Chapple, A. G., Chyr, J. & Deep, G. Syntaxin 6: a novel predictive and prognostic biomarker in papillary renal cell carcinoma. Sci. Rep. 9, 3146 (2019).","journal-title":"Sci. Rep."},{"key":"233_CR40","doi-asserted-by":"publisher","first-page":"E211","DOI":"10.1111\/j.1464-410X.2012.11655.x","volume":"112","author":"I Sakai","year":"2013","unstructured":"Sakai, I., Miyake, H. & Fujisawa, M. Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation. BJU Int. 112, E211\u2013E220 (2013).","journal-title":"BJU Int."},{"key":"233_CR41","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1038\/bjc.2013.602","volume":"109","author":"K Harada","year":"2013","unstructured":"Harada, K., Miyake, H., Kumano, M. & Fujisawa, M. Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2. Br. J. Cancer 109, 2389\u20132395 (2013).","journal-title":"Br. J. Cancer"},{"key":"233_CR42","first-page":"393","volume":"14","author":"KJ Pulkkanen","year":"2000","unstructured":"Pulkkanen, K. J. et al. Characterization of a new animal model for human renal cell carcinoma. In Vivo 14, 393\u2013400 (2000).","journal-title":"Vivo"},{"key":"233_CR43","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1002\/1097-0142(197612)38:6<2469::AID-CNCR2820380636>3.0.CO;2-R","volume":"38","author":"R Mancilla-Jimenez","year":"1976","unstructured":"Mancilla-Jimenez, R., Stanley, R. J. & Blath, R. A. Papillary renal cell carcinoma: a clinical, radiologic, and pathologic study of 34 cases. Cancer 38, 2469\u20132480 (1976).","journal-title":"Cancer"},{"key":"233_CR44","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1158\/1541-7786.MCR-11-0302","volume":"9","author":"B Kucejova","year":"2011","unstructured":"Kucejova, B. et al. Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma. Mol. Cancer. Res. 9, 1255\u20131265 (2011).","journal-title":"Mol. Cancer. Res."},{"key":"233_CR45","first-page":"1092","volume":"55","author":"NJ Whaley JM","year":"1994","unstructured":"Whaley JM, N. J. et al. Germ-line mutations in the von Hippel\u2013Lindau tumor-suppressor gene are similar to somatic von Hippel\u2013Lindau aberrations in sporadic renal cell carcinoma. Am. J. Hum. Genet. 55, 1092\u20131102 (1994).","journal-title":"Am. J. Hum. Genet."},{"key":"233_CR46","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1002\/1878-0261.12346","volume":"12","author":"RM Saleeb","year":"2018","unstructured":"Saleeb, R. M. et al. Modulating ATP binding cassette transporters in papillary renal cell carcinoma type 2 enhances its response to targeted molecular therapy. Mol. Oncol. 12, 1673\u20131688 (2018).","journal-title":"Mol. Oncol."},{"key":"233_CR47","first-page":"S21","volume":"1","author":"KA Furge","year":"2007","unstructured":"Furge, K. A. et al. Combining differential expression, chromosomal and pathway analyses for the molecular characterization of renal cell carcinoma. Can. Urol. Assoc. J. 1, S21\u2013S27 (2007).","journal-title":"Can. Urol. Assoc. J."},{"key":"233_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2985-7","volume":"17","author":"D Matak","year":"2017","unstructured":"Matak, D. et al. Functional significance of CD105-positive cells in papillary renal cell carcinoma. BMC Cancer 17, 21 (2017).","journal-title":"BMC Cancer"},{"key":"233_CR49","doi-asserted-by":"publisher","first-page":"10723","DOI":"10.18632\/oncotarget.24112","volume":"9","author":"C Sourbier","year":"2018","unstructured":"Sourbier, C. et al. Targeting loss of the Hippo signaling pathway in NF2-deficient papillary kidney cancers. Oncotarget 9, 10723\u201310733 (2018).","journal-title":"Oncotarget"},{"key":"233_CR50","first-page":"6639","volume":"35","author":"V Perrier-Trudova","year":"2015","unstructured":"Perrier-Trudova, V. et al. Fumarate hydratase-deficient cell line NCCFH1 as a new in vitro model of hereditary papillary renal cell carcinoma Type 2. Anticancer Res. 35, 6639\u20136653 (2015).","journal-title":"Anticancer Res."},{"key":"233_CR51","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.cancergen.2012.05.001","volume":"205","author":"Y Yang","year":"2012","unstructured":"Yang, Y. et al. A novel fumarate hydratase-deficient HLRCC kidney cancer cell line, UOK268: a model of the Warburg effect in cancer. Cancer Genet. 205, 377\u2013390 (2012).","journal-title":"Cancer Genet."},{"key":"233_CR52","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cancergencyto.2009.08.018","volume":"196","author":"Y Yang","year":"2010","unstructured":"Yang, Y. et al. UOK 262 cell line, fumarate hydratase deficient (FH-\/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genet. Cytogenet. 196, 45\u201355 (2010).","journal-title":"Cancer Genet. Cytogenet."},{"key":"233_CR53","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1158\/0008-5472.CAN-09-3722","volume":"70","author":"D Huang","year":"2010","unstructured":"Huang, D. et al. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res. 70, 1053\u20131062 (2010).","journal-title":"Cancer Res."},{"key":"233_CR54","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s00432-014-1883-0","volume":"141","author":"L Wang","year":"2015","unstructured":"Wang, L., Park, P., La Marca, F., Than, K. D. & Lin,\u00a0C.\u00a0Y. BMP-2 inhibits tumor-initiating ability in human renal cancer stem cells and induces bone formation. J. Cancer Res. Clin. Oncol. 141, 1013\u20131024 (2015).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"233_CR55","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s12094-015-1457-x","volume":"18","author":"A Miyazaki","year":"2016","unstructured":"Miyazaki, A., Miyake, H. & Fujisawa, M. Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells. Clin. Transl Oncol. 18, 893\u2013900 (2016).","journal-title":"Clin. Transl Oncol."},{"key":"233_CR56","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2165\/11318860-000000000-00000","volume":"23","author":"GS Papaetis","year":"2009","unstructured":"Papaetis, G. S. & Syrigos, K. N. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs 23, 377\u2013389 (2009).","journal-title":"BioDrugs"},{"key":"233_CR57","first-page":"1","volume":"1855","author":"SC Joosten","year":"2015","unstructured":"Joosten, S. C. et al. Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives. Biochim. Biophys. Acta 1855, 1\u201316 (2015).","journal-title":"Biochim. Biophys. Acta"},{"key":"233_CR58","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00345-011-0767-z","volume":"30","author":"TE Behbahani","year":"2012","unstructured":"Behbahani, T. E. et al. Tyrosine kinase expression profile in clear cell renal cell carcinoma. World J. Urol. 30, 559\u2013565 (2012).","journal-title":"World J. Urol."},{"key":"233_CR59","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1093\/jnci\/djn188","volume":"100","author":"J Wu","year":"2008","unstructured":"Wu, J. et al. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J. Natl Cancer Inst. 100, 926\u2013939 (2008).","journal-title":"J. Natl Cancer Inst."},{"key":"233_CR60","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S1359-6101(99)00019-2","volume":"10","author":"H Mano","year":"1999","unstructured":"Mano, H. Tec family of protein-tyrosine kinases: an overview of their structure and function. Cytokine Growth Factor Rev. 10, 267\u2013280 (1999).","journal-title":"Cytokine Growth Factor Rev."},{"key":"233_CR61","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1756-9966-33-25","volume":"33","author":"J Zhuang","year":"2014","unstructured":"Zhuang, J. et al. The expression and role of tyrosine kinase ETK\/BMX in renal cell carcinoma. J. Exp. Clin. Cancer Res. 33, 25 (2014).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"233_CR62","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1038\/sj.onc.1202687","volume":"18","author":"LY Xue","year":"1999","unstructured":"Xue, L. Y., Qiu, Y., He, J., Kung, H. J. & Oleinick, N. L. Etk\/Bmx, a PH-domain containing tyrosine kinase, protects prostate cancer cells from apoptosis induced by photodynamic therapy or thapsigargin. Oncogene 18, 3391\u20133398 (1999).","journal-title":"Oncogene"},{"key":"233_CR63","first-page":"6870470","volume":"2016","author":"L Wang","year":"2016","unstructured":"Wang, L. et al. Prognostic and predictive values of subcellular localisation of ret in renal clear-cell carcinoma. Dis. Markers 2016, 6870470 (2016).","journal-title":"Dis. Markers"},{"key":"233_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2016.04.023","volume":"377","author":"C Lin","year":"2016","unstructured":"Lin, C. et al. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma. Cancer Lett. 377, 1\u201310 (2016).","journal-title":"Cancer Lett."},{"key":"233_CR65","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1002\/cncr.26540","volume":"118","author":"SE Abdullah","year":"2012","unstructured":"Abdullah, S. E. & Perez-Soler, R. Mechanisms of resistance to vascular endothelial growth factor blockade. Cancer 118, 3455\u20133467 (2012).","journal-title":"Cancer"},{"key":"233_CR66","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s12013-013-9723-4","volume":"68","author":"H Gao","year":"2014","unstructured":"Gao, H. & Deng, L. Sphingosine kinase-1 activation causes acquired resistance against Sunitinib in renal cell carcinoma cells. Cell Biochem. Biophys. 68, 419\u2013425 (2014).","journal-title":"Cell Biochem. Biophys."},{"key":"233_CR67","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1158\/1078-0432.CCR-08-0145","volume":"14","author":"S Awasthi","year":"2008","unstructured":"Awasthi, S. et al. RLIP76 and cancer. Clin. Cancer Res. 14, 4372\u20134377 (2008).","journal-title":"Clin. Cancer Res."},{"key":"233_CR68","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1002\/ijc.24767","volume":"126","author":"SS Singhal","year":"2010","unstructured":"Singhal, S. S. et al. Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. Int. J. Cancer 126, 1327\u20131338 (2010).","journal-title":"Int. J. Cancer"},{"key":"233_CR69","doi-asserted-by":"publisher","first-page":"4244","DOI":"10.1158\/0008-5472.CAN-08-3521","volume":"69","author":"SS Singhal","year":"2009","unstructured":"Singhal, S. S. et al. RLIP76: a target for kidney cancer therapy. Cancer Res. 69, 4244\u20134251 (2009).","journal-title":"Cancer Res."},{"key":"233_CR70","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1158\/0008-5472.CAN-05-3534","volume":"66","author":"SS Singhal","year":"2006","unstructured":"Singhal, S. S., Awasthi, Y. C. & Awasthi, S. Regression of melanoma in a murine model by RLIP76 depletion. Cancer Res. 66, 2354\u20132360 (2006).","journal-title":"Cancer Res."},{"key":"233_CR71","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.1158\/0008-5472.CAN-06-4124","volume":"67","author":"SS Singhal","year":"2007","unstructured":"Singhal, S. S. et al. Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (Ral-binding protein 1). Cancer Res. 67, 4382\u20134389 (2007).","journal-title":"Cancer Res."},{"key":"233_CR72","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1007\/s11095-015-1723-1","volume":"32","author":"SS Singhal","year":"2015","unstructured":"Singhal, S. S., Singhal, J., Figarola, J., Horne, D. & Awasthi, S. RLIP76 targeted therapy for kidney cancer. Pharm. Res. 32, 3123\u20133136 (2015).","journal-title":"Pharm. Res."},{"key":"233_CR73","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature12912","volume":"505","author":"MS Lawrence","year":"2014","unstructured":"Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495\u2013501 (2014).","journal-title":"Nature"},{"key":"233_CR74","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/5042","volume":"21","author":"L Shayesteh","year":"1999","unstructured":"Shayesteh, L. et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet. 21, 99\u2013102 (1999).","journal-title":"Nat. Genet."},{"key":"233_CR75","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1126\/science.1096502","volume":"304","author":"Y Samuels","year":"2004","unstructured":"Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004).","journal-title":"Science"},{"key":"233_CR76","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jgg.2015.03.003","volume":"42","author":"H Guo","year":"2015","unstructured":"Guo, H. et al. The PI3K\/AKT pathway and renal cell carcinoma. J. Genet. Genomics 42, 343\u2013353 (2015).","journal-title":"J. Genet. Genomics"},{"key":"233_CR77","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1111\/j.1582-4934.2008.00488.x","volume":"13","author":"M Hager","year":"2009","unstructured":"Hager, M. et al. Increased activated Akt expression in renal cell carcinomas and prognosis. J. Cell Mol. Med. 13, 2181\u20132188 (2009).","journal-title":"J. Cell Mol. Med."},{"key":"233_CR78","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.semcdb.2004.01.002","volume":"15","author":"J Downward","year":"2004","unstructured":"Downward, J. PI 3-kinase, Akt and cell survival. Semin. Cell Dev. Biol. 15, 177\u2013182 (2004).","journal-title":"Semin. Cell Dev. Biol."},{"key":"233_CR79","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/path.1611","volume":"204","author":"AR Panigrahi","year":"2004","unstructured":"Panigrahi, A. R. et al. The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J. Pathol. 204, 93\u2013100 (2004).","journal-title":"J. Pathol."},{"key":"233_CR80","doi-asserted-by":"publisher","first-page":"4240","DOI":"10.1073\/pnas.96.8.4240","volume":"96","author":"LC Cantley","year":"1999","unstructured":"Cantley, L. C. & Neel, B. G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase\/AKT pathway. Proc. Natl Acad. Sci. 96, 4240\u20134245 (1999).","journal-title":"Proc. Natl Acad. Sci."},{"key":"233_CR81","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s13577-015-0112-8","volume":"28","author":"H Tei","year":"2015","unstructured":"Tei, H., Miyake, H. & Fujisawa, M. Enhanced sensitivity to sorafenib by inhibition of Akt1 expression in human renal cell carcinoma ACHN cells both in vitro and in vivo. Hum. Cell 28, 114\u2013121 (2015).","journal-title":"Hum. Cell"},{"key":"233_CR82","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s12094-013-1151-9","volume":"16","author":"K Harada","year":"2014","unstructured":"Harada, K., Miyake, H., Kusuda, Y. & Fujisawa, M. Characterization of mechanism involved in acquired resistance to sorafenib in a mouse renal cell cancer RenCa model. Clin. Transl Oncol. 16, 801\u2013806 (2014).","journal-title":"Clin. Transl. Oncol."},{"key":"233_CR83","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/sj.cr.7290105","volume":"12","author":"W Zhang","year":"2002","unstructured":"Zhang, W. & Liu, H. T. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 12, 9\u201318 (2002).","journal-title":"Cell Res."},{"key":"233_CR84","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1126\/science.286.5445.1738","volume":"286","author":"C Rommel","year":"1999","unstructured":"Rommel, C. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 286, 1738\u20131741 (1999).","journal-title":"Science"},{"key":"233_CR85","doi-asserted-by":"crossref","unstructured":"Ho, J. Y. et al. Ovatodiolide targets beta -catenin signaling in suppressing tumorigenesis and overcoming drug resistance in renal cell carcinoma. Evid. Based Complement. Alternat. Med. 2013, 2013).","DOI":"10.1155\/2013\/161628"},{"key":"233_CR86","doi-asserted-by":"publisher","first-page":"757908","DOI":"10.1155\/2010\/757908","volume":"2010","author":"S Biswas","year":"2010","unstructured":"Biswas, S. et al. Effects of HIF-1alpha and HIF2alpha on growth and metabolism of clear-cell renal cell carcinoma 786-0 xenografts. J. Oncol. 2010, 757908 (2010).","journal-title":"J. Oncol."},{"key":"233_CR87","first-page":"7403","volume":"17","author":"S Zhang","year":"2018","unstructured":"Zhang, S., Ren, Y. & Qiu, J. Dauricine inhibits viability and induces cell cycle arrest and apoptosis via inhibiting the PI3K\/Akt signaling pathway in renal cell carcinoma cells. Mol. Med. Rep. 17, 7403\u20137408 (2018).","journal-title":"Mol. Med. Rep."},{"key":"233_CR88","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01239342 (2017)."},{"key":"233_CR89","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01480154 (2019)."},{"key":"233_CR90","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03673787 (2018)."},{"key":"233_CR91","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02019693 (2019)."},{"key":"233_CR92","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1756-9966-28-40","volume":"28","author":"G Dorevic","year":"2009","unstructured":"Dorevic, G. et al. Hypoxia inducible factor-1alpha correlates with vascular endothelial growth factor A and C indicating worse prognosis in clear cell renal cell carcinoma. J. Exp. Clin. Cancer Res. 28, 40 (2009).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"233_CR93","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1177\/1947601911423654","volume":"2","author":"BL Krock","year":"2011","unstructured":"Krock, B. L., Skuli, N. & Simon, M. C. Hypoxia-induced angiogenesis: good and evil. Genes Cancer 2, 1117\u20131133 (2011).","journal-title":"Genes Cancer"},{"key":"233_CR94","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ccr.2007.02.006","volume":"11","author":"JD Gordan","year":"2007","unstructured":"Gordan, J. D., Bertout, J. A., Hu, C. J., Diehl, J. A. & Simon, M. C. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 11, 335\u2013347 (2007).","journal-title":"Cancer Cell"},{"key":"233_CR95","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.4161\/cc.8.9.8303","volume":"8","author":"MY Koh","year":"2009","unstructured":"Koh, M. Y. & Powis, G. HAF: the new player in oxygen-independent HIF-1alpha degradation. Cell Cycle 8, 1359\u20131366 (2009).","journal-title":"Cell Cycle"},{"key":"233_CR96","doi-asserted-by":"crossref","first-page":"49713","DOI":"10.18632\/oncotarget.17923","volume":"8","author":"XM Lai","year":"2017","unstructured":"Lai, X. M. et al. HAF mediates the evasive resistance of anti-angiogenesis TKI through disrupting HIF-1alpha and HIF-2alpha balance in renal cell carcinoma. Oncotarget 8, 49713\u201349724 (2017).","journal-title":"Oncotarget"},{"key":"233_CR97","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13578-017-0197-8","volume":"7","author":"ZF Bielecka","year":"2017","unstructured":"Bielecka, Z. F. et al. Hypoxic 3D in vitro culture models reveal distinct resistance processes to TKIs in renal cancer cells. Cell Biosci. 7, 71 (2017).","journal-title":"Cell Biosci."},{"key":"233_CR98","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.2","volume":"6","author":"Y Zhu","year":"2015","unstructured":"Zhu, Y. et al. p21-activated kinase 1 determines stem-like phenotype and sunitinib resistance via NF-kappaB\/IL-6 activation in renal cell carcinoma. Cell Death Dis. 6, e1637 (2015).","journal-title":"Cell Death Dis."},{"key":"233_CR99","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02293980 (2008)."},{"key":"233_CR100","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1200\/JCO.2017.74.2627","volume":"36","author":"KD Courtney","year":"2018","unstructured":"Courtney, K. D. et al. Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2alpha antagonist in patients with previously treated advanced clear cell renal cell carcinoma. J. Clin. Oncol. 36, 867\u2013874 (2018).","journal-title":"J. Clin. Oncol."},{"key":"233_CR101","doi-asserted-by":"publisher","first-page":"6321","DOI":"10.1158\/0008-5472.CAN-17-1589","volume":"77","author":"H Yoshino","year":"2017","unstructured":"Yoshino, H. et al. PHGDH as a key enzyme for serine biosynthesis in HIF2alpha-targeting therapy for renal cell carcinoma. Cancer Res. 77, 6321\u20136329 (2017).","journal-title":"Cancer Res."},{"key":"233_CR102","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1002\/stem.1995","volume":"33","author":"X Hu","year":"2015","unstructured":"Hu, X. et al. Heparanase released from mesenchymal stem cells activates integrin beta1\/HIF-2alpha\/Flk-1 signaling and promotes endothelial cell migration and angiogenesis. Stem Cells 33, 1850\u20131862 (2015).","journal-title":"Stem Cells"},{"key":"233_CR103","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1046\/j.1523-1755.2002.00206.x","volume":"61","author":"A Horiguchi","year":"2002","unstructured":"Horiguchi, A., Oya, M., Marumo, K. & Murai, M. STAT3, but not ERKs, mediates the IL-6-induced proliferation of renal cancer cells, ACHN and 769P. Kidney Int. 61, 926\u2013938 (2002).","journal-title":"Kidney Int."},{"key":"233_CR104","first-page":"590","volume":"55","author":"Y Mizutani","year":"1995","unstructured":"Mizutani, Y. et al. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res. 55, 590\u2013596 (1995).","journal-title":"Cancer Res."},{"key":"233_CR105","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1080\/19336918.2017.1307482","volume":"12","author":"Y Chen","year":"2017","unstructured":"Chen, Y. et al. IL-6 is involved in malignancy and doxorubicin sensitivity of renal carcinoma cells. Cell Adh. Migr. 12, 28\u201336 (2017).","journal-title":"Cell Adh. Migr"},{"key":"233_CR106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15586\/jkcvhl.2018.106","volume":"5","author":"H Kamli","year":"2018","unstructured":"Kamli, H., Glenda, G. C., Li, L., Vesey, D. A. & Morais, C. Characterisation of the morphological, functional and molecular changes in sunitinib-resistant renal cell carcinoma cells. J. Kidney Cancer VHL 5, 1\u20139 (2018).","journal-title":"J. Kidney Cancer VHL"},{"key":"233_CR107","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1158\/0008-5472.CAN-09-3965","volume":"70","author":"D Huang","year":"2010","unstructured":"Huang, D. et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 70, 1063\u20131071 (2010).","journal-title":"Cancer Res."},{"key":"233_CR108","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.urolonc.2013.10.018","volume":"32","author":"LK Bi","year":"2014","unstructured":"Bi, L. K. et al. Kidney cancer cells secrete IL-8 to activate Akt and promote migration of mesenchymal stem cells. Urol. Oncol. 32, 607\u2013612 (2014).","journal-title":"Urologic Oncol."},{"key":"233_CR109","doi-asserted-by":"crossref","first-page":"44478","DOI":"10.18632\/oncotarget.9873","volume":"7","author":"Z Yang","year":"2016","unstructured":"Yang, Z., Xie, H., He, D. & Li, L. Infiltrating macrophages increase RCC epithelial mesenchymal transition (EMT) and stem cell-like populations via AKT and mTOR signaling. Oncotarget 7, 44478\u201344491 (2016).","journal-title":"Oncotarget"},{"key":"233_CR110","first-page":"147","volume":"7","author":"Y Cai","year":"2009","unstructured":"Cai, Y., Yu, X., Hu, S. & Yu, J. A brief review on the mechanisms of miRNA regulation. Genomics Proteomics. Bioinformatics 7, 147\u2013154 (2009).","journal-title":"Bioinformatics"},{"key":"233_CR111","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0086263","volume":"9","author":"C Prior","year":"2014","unstructured":"Prior, C. et al. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma. PLOS ONE 9, e86263 (2014).","journal-title":"PLOS ONE"},{"key":"233_CR112","first-page":"2985","volume":"37","author":"N Yamaguchi","year":"2017","unstructured":"Yamaguchi, N. et al. Identification of microRNAs involved in resistance to sunitinib in renal cell carcinoma cells. Anticancer Res. 37, 2985\u20132992 (2017).","journal-title":"Anticancer Res."},{"key":"233_CR113","doi-asserted-by":"publisher","first-page":"D239","DOI":"10.1093\/nar\/gkv1258","volume":"44","author":"CH Chou","year":"2016","unstructured":"Chou, C. H. et al. miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database. Nucleic Acids Res. 44, D239\u2013D247 (2016).","journal-title":"Nucleic Acids Res."},{"key":"233_CR114","doi-asserted-by":"publisher","first-page":"W169","DOI":"10.1093\/nar\/gkt393","volume":"41","author":"MD Paraskevopoulou","year":"2013","unstructured":"Paraskevopoulou, M. D. et al. DIANA-microT web serverv5.0: service integration into miRNA functional analysis workflows. Nucleic Acids Res. 41, W169\u2013W173 (2013).","journal-title":"Nucleic Acids Res."},{"key":"233_CR115","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1128\/MCB.00189-16","volume":"36","author":"TA Tran","year":"2016","unstructured":"Tran, T. A. et al. Fibroblast growth factor receptor-dependent and -independent paracrine signaling by sunitinib-resistant renal cell carcinoma. Mol. Cell Biol. 36, 1836\u20131855 (2016).","journal-title":"Mol. Cell Biol."},{"key":"233_CR116","doi-asserted-by":"publisher","first-page":"W498","DOI":"10.1093\/nar\/gks494","volume":"40","author":"IS Vlachos","year":"2012","unstructured":"Vlachos, I. S. et al. DIANA miRPath v.2.0: investigating the combinatorial effect of microRNAs in pathways. Nucleic Acids Res. 40, W498\u2013W504 (2012).","journal-title":"Nucleic Acids Res."},{"key":"233_CR117","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/jpi.12308","volume":"60","author":"YW Lin","year":"2016","unstructured":"Lin, Y. W. et al. Melatonin inhibits MMP-9 transactivation and renal cell carcinoma metastasis by suppressing Akt-MAPKs pathway and NF-kappaB DNA-binding activity. J. Pineal. Res. 60, 277\u2013290 (2016).","journal-title":"J. Pineal. Res."},{"key":"233_CR118","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.3892\/ijo.2013.2073","volume":"43","author":"A Sato","year":"2013","unstructured":"Sato, A. et al. Inhibition of MMP-9 using a pyrrole-imidazole polyamide reduces cell invasion in renal cell carcinoma. Int. J. Oncol. 43, 1441\u20131446 (2013).","journal-title":"Int. J. Oncol."},{"key":"233_CR119","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","volume":"14","author":"T Shibue","year":"2017","unstructured":"Shibue, T. & Weinberg, R. A. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat. Rev. Clin. Oncol. 14, 611\u2013629 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"233_CR120","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.bbrc.2016.03.048","volume":"473","author":"GC Gobe","year":"2016","unstructured":"Gobe, G. C. et al. Decreased apoptosis repressor with caspase recruitment domain confers resistance to sunitinib in renal cell carcinoma through alternate angiogenesis pathways. Biochem. Biophys. Res. Commun. 473, 47\u201353 (2016).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"233_CR121","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.molcel.2004.08.020","volume":"15","author":"YJ Nam","year":"2004","unstructured":"Nam, Y. J. et al. Inhibition of both the extrinsic and intrinsic death pathways through nonhomotypic death-fold interactions. Mol. Cell 15, 901\u2013912 (2004).","journal-title":"Mol. Cell"},{"key":"233_CR122","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/cdd.2014.31","volume":"21","author":"B Auffinger","year":"2014","unstructured":"Auffinger, B. et al. Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy. Cell Death Differ. 21, 1119\u20131131 (2014).","journal-title":"Cell Death. Differ."},{"key":"233_CR123","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1084\/jem.20111424","volume":"209","author":"P Hamerlik","year":"2012","unstructured":"Hamerlik, P. et al. Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J. Exp. Med. 209, 507\u2013520 (2012).","journal-title":"J. Exp. Med."},{"key":"233_CR124","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/978-94-007-0782-5_9","volume":"714","author":"C Nagler","year":"2011","unstructured":"Nagler, C., Zanker, K. S. & Dittmar, T. Cell fusion, drug resistance and recurrence CSCs. Adv. Exp. Med. Biol. 714, 173\u2013182 (2011).","journal-title":"Adv. Exp. Med. Biol."},{"key":"233_CR125","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1158\/1541-7786.MCR-08-0393","volume":"7","author":"F Jiang","year":"2009","unstructured":"Jiang, F. et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol. Cancer Res. 7, 330\u2013338 (2009).","journal-title":"Mol. Cancer Res."},{"key":"233_CR126","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.stem.2007.10.015","volume":"1","author":"D Balicki","year":"2007","unstructured":"Balicki, D. Moving forward in human mammary stem cell biology and breast cancer prognostication using ALDH1. Cell Stem Cell 1, 485\u2013487 (2007).","journal-title":"Cell Stem Cell"},{"key":"233_CR127","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/leu.2013.383","volume":"28","author":"W Zhou","year":"2014","unstructured":"Zhou, W. et al. ALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signatures in multiple myeloma. Leukemia 28, 1155\u20131158 (2014).","journal-title":"Leukemia"},{"key":"233_CR128","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1634\/stemcells.2004-0292","volume":"23","author":"DJ Pearce","year":"2005","unstructured":"Pearce, D. J. et al. Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells 23, 752\u2013760 (2005).","journal-title":"Stem Cells"},{"key":"233_CR129","doi-asserted-by":"crossref","unstructured":"Rabinovich, I. et al. Cancer stem cell markers ALDH1 and CD44+\/CD24- phenotype and their prognosis impact in invasive ductal carcinoma. Eur. J. Histochem. 62, (2018).","DOI":"10.4081\/ejh.2018.2943"},{"key":"233_CR130","doi-asserted-by":"publisher","unstructured":"Mohamed, S. Y. et al. The prognostic value of cancer stem cell markers (Notch1, ALDH1, and CD44) in primary colorectal carcinoma. J. Gastrointest. Cancer https:\/\/doi.org\/10.1007\/s12029-018-0156-6 (2018).","DOI":"10.1007\/s12029-018-0156-6"},{"key":"233_CR131","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.7150\/jca.18955","volume":"8","author":"MJ Kim","year":"2017","unstructured":"Kim, M. J. et al. Correlation of ALDH1 and Notch3 expression: clinical implication in ovarian carcinomas. J. Cancer 8, 3331\u20133342 (2017).","journal-title":"J. Cancer"},{"key":"233_CR132","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0165718","volume":"11","author":"MI Khan","year":"2016","unstructured":"Khan, M. I. et al. Comparative gene expression profiling of primary and metastatic renal cell carcinoma stem cell-like cancer cells. PLOS ONE 11, e0165718 (2016).","journal-title":"PLOS ONE"},{"key":"233_CR133","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075463","volume":"8","author":"K Ueda","year":"2013","unstructured":"Ueda, K. et al. Aldehyde dehydrogenase 1 identifies cells with cancer stem cell-like properties in a human renal cell carcinoma cell line. PLOS ONE 8, e75463 (2013).","journal-title":"PLOS ONE"},{"key":"233_CR134","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1073\/pnas.1018866109","volume":"109","author":"SJ Conley","year":"2012","unstructured":"Conley, S. J. et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc. Natl Acad. Sci. USA 109, 2784\u20132789 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"233_CR135","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nrc1892","volume":"6","author":"R Kumar","year":"2006","unstructured":"Kumar, R., Gururaj, A. E. & Barnes, C. J. p21-activated kinases in cancer. Nat. Rev. Cancer 6, 459\u2013471 (2006).","journal-title":"Nat. Rev. Cancer"},{"key":"233_CR136","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1002\/ijc.22893","volume":"121","author":"GC O\u2019Sullivan","year":"2007","unstructured":"O\u2019Sullivan, G. C. et al. Modulation of p21-activated kinase 1 alters the behavior of renal cell carcinoma. Int. J. Cancer 121, 1930\u20131940 (2007).","journal-title":"Int. J. Cancer"},{"key":"233_CR137","doi-asserted-by":"publisher","first-page":"17448","DOI":"10.1073\/pnas.0508888102","volume":"102","author":"KV Gurova","year":"2005","unstructured":"Gurova, K. V. et al. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc. Natl Acad. Sci. USA 102, 17448\u201317453 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"233_CR138","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S0898-6568(03)00087-1","volume":"15","author":"RE Menard","year":"2003","unstructured":"Menard, R. E. & Mattingly, R. R. Cell surface receptors activate p21-activated kinase 1 via multiple Ras and PI3-kinase-dependent pathways. Cell. Signal. 15, 1099\u20131109 (2003).","journal-title":"Cell. Signal."},{"key":"233_CR139","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s13402-015-0218-8","volume":"38","author":"KJ Gotink","year":"2015","unstructured":"Gotink, K. J. et al. Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib. Cell Oncol. 38, 119\u2013129 (2015).","journal-title":"Cell Oncol. (Dordr.)"},{"key":"233_CR140","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/bjc.2013.360","volume":"109","author":"R Rosa","year":"2013","unstructured":"Rosa, R. et al. Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer. Br. J. Cancer 109, 686\u2013693 (2013).","journal-title":"Br. J. Cancer"},{"key":"233_CR141","first-page":"893","volume":"15","author":"T Yumioka","year":"2018","unstructured":"Yumioka, T. et al. Lysosome-associated membrane protein 2 (LAMP-2) expression induced by miR-194-5p downregulation contributes to sunitinib resistance in human renal cell carcinoma cells. Oncol. Lett. 15, 893\u2013900 (2018).","journal-title":"Oncol. Lett."},{"key":"233_CR142","doi-asserted-by":"publisher","first-page":"E250","DOI":"10.1111\/j.1464-410X.2011.10186.x","volume":"108","author":"C Porta","year":"2011","unstructured":"Porta, C. et al. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int. 108, E250\u2013E257 (2011).","journal-title":"BJU Int."},{"key":"233_CR143","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.eururo.2015.04.017","volume":"68","author":"C Eichelberg","year":"2015","unstructured":"Eichelberg, C. et al. SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib-sorafenib in the treatment of metastatic renal cell cancer. Eur. Urol. 68, 837\u2013847 (2015).","journal-title":"Eur. Urol."},{"key":"233_CR144","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1016\/j.ejca.2013.02.032","volume":"49","author":"R Iacovelli","year":"2013","unstructured":"Iacovelli, R. et al. Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort. Eur. J. Cancer 49, 2134\u20132142 (2013).","journal-title":"Eur. J. Cancer"},{"key":"233_CR145","doi-asserted-by":"publisher","first-page":"1726078","DOI":"10.1155\/2017\/1726078","volume":"2017","author":"S Faes","year":"2017","unstructured":"Faes, S., Demartines, N. & Dormond, O. Resistance to mTORC1 inhibitors in cancer therapy: from kinase mutations to intratumoral heterogeneity of kinase activity. Oxid. Med. Cell Longev. 2017, 1726078 (2017).","journal-title":"Oxid. Med. Cell Longev."},{"key":"233_CR146","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S1097-2765(02)00636-6","volume":"10","author":"R Loewith","year":"2002","unstructured":"Loewith, R. et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 10, 457\u2013468 (2002).","journal-title":"Mol. Cell"},{"key":"233_CR147","doi-asserted-by":"publisher","first-page":"686984","DOI":"10.1155\/2014\/686984","volume":"2014","author":"M Showkat","year":"2014","unstructured":"Showkat, M., Beigh, M. A. & Andrabi, K. I. mTOR signaling in protein translation regulation: implications in cancer genesis and therapeutic interventions. Mol. Biol. Int. 2014, 686984 (2014).","journal-title":"Mol. Biol. Int."},{"key":"233_CR148","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1038\/onc.2010.139","volume":"29","author":"CA Sparks","year":"2010","unstructured":"Sparks, C. A. & Guertin, D. A. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 29, 3733\u20133744 (2010).","journal-title":"Oncogene"},{"key":"233_CR149","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11523-011-0167-8","volume":"6","author":"JS Carew","year":"2011","unstructured":"Carew, J. S., Kelly, K. R. & Nawrocki, S. T. Mechanisms of mTOR inhibitor resistance in cancer therapy. Target Oncol. 6, 17\u201327 (2011).","journal-title":"Target Oncol."},{"key":"233_CR150","first-page":"3065","volume":"118","author":"A Carracedo","year":"2008","unstructured":"Carracedo, A. et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 118, 3065\u20133074 (2008).","journal-title":"J. Clin. Invest."},{"key":"233_CR151","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1158\/1078-0432.CCR-09-3022","volume":"16","author":"DC Cho","year":"2010","unstructured":"Cho, D. C. et al. The efficacy of the novel dual PI3-kinase\/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin. Cancer Res. 16, 3628\u20133638 (2010).","journal-title":"Clin. Cancer Res."},{"key":"233_CR152","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1158\/1535-7163.MCT-11-0446","volume":"10","author":"JJ Wallin","year":"2011","unstructured":"Wallin, J. J. et al. GDC-0980 is a novel class I PI3K\/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol. Cancer Ther. 10, 2426\u20132436 (2011).","journal-title":"Mol. Cancer Ther."},{"key":"233_CR153","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1634\/theoncologist.2016-0145","volume":"21","author":"MI Carlo","year":"2016","unstructured":"Carlo, M. I. et al. A Phase Ib Study of BEZ235, a dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (MTOR), in patients with advanced renal cell carcinoma. Oncologist 21, 787\u2013788 (2016).","journal-title":"Oncologist"},{"key":"233_CR154","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1200\/JCO.2015.64.8808","volume":"34","author":"T Powles","year":"2016","unstructured":"Powles, T. et al. Randomized open-label phase II trial of apitolisib (GDC-0980), a novel inhibitor of the PI3K\/mammalian target of rapamycin pathway, versus everolimus in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 34, 1660\u20131668 (2016).","journal-title":"J. Clin. Oncol."},{"key":"233_CR155","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.eururo.2015.08.035","volume":"69","author":"T Powles","year":"2016","unstructured":"Powles, T. et al. A randomised phase 2 study of AZD2014 versus everolimus in patients with VEGF-refractory metastatic clear cell renal cancer. Eur. Urol. 69, 450\u2013456 (2016).","journal-title":"Eur. Urol."},{"key":"233_CR156","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1093\/annonc\/mdx104","volume":"28","author":"PJ Vlachostergios","year":"2017","unstructured":"Vlachostergios, P. J. & Molina, A. M. PI3K\/AKT inhibitors in patients with refractory renal cell carcinoma: what have we learnt so far? Ann. Oncol. 28, 914\u2013916 (2017).","journal-title":"Ann. Oncol."},{"key":"233_CR157","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1158\/0008-5472.CAN-13-1729","volume":"74","author":"A Lin","year":"2014","unstructured":"Lin, A. et al. FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway. Cancer Res. 74, 1682\u20131693 (2014).","journal-title":"Cancer Res."},{"key":"233_CR158","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.pharmthera.2014.11.016","volume":"148","author":"E Beurel","year":"2015","unstructured":"Beurel, E., Grieco, S. F. & Jope, R. S. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol. Ther. 148, 114\u2013131 (2015).","journal-title":"Pharmacol. Ther."},{"key":"233_CR159","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1242\/jcs.00384","volume":"116","author":"BW Doble","year":"2003","unstructured":"Doble, B. W. & Woodgett, J. R. GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. 116, 1175\u20131186 (2003).","journal-title":"J Cell Sci."},{"key":"233_CR160","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2418-7","volume":"16","author":"H Ito","year":"2016","unstructured":"Ito, H. et al. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition. BMC Cancer 16, 393 (2016).","journal-title":"BMC Cancer"},{"key":"233_CR161","doi-asserted-by":"publisher","first-page":"45937","DOI":"10.1074\/jbc.M306268200","volume":"278","author":"R Bhat","year":"2003","unstructured":"Bhat, R. et al. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J. Biol. Chem. 278, 45937\u201345945 (2003).","journal-title":"J. Biol. Chem."},{"key":"233_CR162","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.bbrc.2012.05.147","volume":"423","author":"H Kawazoe","year":"2012","unstructured":"Kawazoe, H. et al. GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC). Biochem. Biophys. Res. Commun. 423, 490\u2013495 (2012).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"233_CR163","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1038\/sj.bjc.6605437","volume":"101","author":"V Bilim","year":"2009","unstructured":"Bilim, V. et al. Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma. Br. J. Cancer 101, 2005\u20132014 (2009).","journal-title":"Br. J. Cancer"},{"key":"233_CR164","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.18632\/oncotarget.2037","volume":"5","author":"JA McCubrey","year":"2014","unstructured":"McCubrey, J. A. et al. GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget 5, 2881\u20132911 (2014).","journal-title":"Oncotarget"},{"key":"233_CR165","doi-asserted-by":"publisher","first-page":"19500","DOI":"10.18632\/oncotarget.3669","volume":"6","author":"AM Holder","year":"2015","unstructured":"Holder, A. M. et al. Epithelial to mesenchymal transition is associated with rapamycin resistance. Oncotarget 6, 19500\u201319513 (2015).","journal-title":"Oncotarget"},{"key":"233_CR166","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/sj.bjc.6604636","volume":"99","author":"C Le Tourneau","year":"2008","unstructured":"Le Tourneau, C., Faivre, S., Serova, M. & Raymond, E. mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work? Br. J. Cancer 99, 1197\u20131203 (2008).","journal-title":"Br. J. Cancer"},{"key":"233_CR167","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1158\/1078-0432.CCR-10-2200","volume":"17","author":"AG Gilmartin","year":"2011","unstructured":"Gilmartin, A. G. et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin. Cancer Res. 17, 989\u20131000 (2011).","journal-title":"Clin. Cancer Res."},{"key":"233_CR168","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1200\/JCO.2012.46.4289","volume":"31","author":"JR Diamond","year":"2013","unstructured":"Diamond, J. R. et al. Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma. J. Clin. Oncol. 31, e254\u2013e258 (2013).","journal-title":"J. Clin. Oncol."},{"key":"233_CR169","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1158\/1078-0432.CCR-14-2685","volume":"21","author":"AG Schuller","year":"2015","unstructured":"Schuller, A. G. et al. The MET inhibitor AZD6094 (savolitinib, HMPL-504) induces regression in papillary renal cell carcinoma patient-derived xenograft models. Clin. Cancer Res. 21, 2811\u20132819 (2015).","journal-title":"Clin. Cancer Res."},{"key":"233_CR170","unstructured":"Stenger, M. Cabozantinib in advanced renal cell carcinoma. ASCO Post http:\/\/www.ascopost.com\/issues\/march-10-2018\/cabozantinib-in-advanced-renal-cell-carcinoma\/ (2018)."},{"key":"233_CR171","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02127710 (2019)."},{"key":"233_CR172","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03091192 (2019)."},{"key":"233_CR173","doi-asserted-by":"publisher","first-page":"793","DOI":"10.2174\/138161282005140214165212","volume":"20","author":"YH Choi","year":"2014","unstructured":"Choi, Y. H. & Yu, A. M. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr. Pharm. Des. 20, 793\u2013807 (2014).","journal-title":"Curr. Pharm. Des."},{"key":"233_CR174","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.bcp.2008.06.007","volume":"76","author":"H Zhu","year":"2008","unstructured":"Zhu, H. et al. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1\/P-glycoprotein expression in human cancer cells. Biochem. Pharmacol. 76, 582\u2013588 (2008).","journal-title":"Biochem. Pharmacol."},{"key":"233_CR175","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13046-018-0677-7","volume":"37","author":"X Fu","year":"2018","unstructured":"Fu, X. et al. Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K\/Akt pathway. J. Exp. Clin. Cancer Res. 37, 52 (2018).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"233_CR176","doi-asserted-by":"publisher","first-page":"6654","DOI":"10.18632\/oncotarget.2208","volume":"5","author":"BV Chakravarthi","year":"2014","unstructured":"Chakravarthi, B. V. et al. The miR-124-prolyl hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression. Oncotarget 5, 6654\u20136669 (2014).","journal-title":"Oncotarget"},{"key":"233_CR177","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1002\/cam4.309","volume":"3","author":"T Jinushi","year":"2014","unstructured":"Jinushi, T. et al. Low expression levels of microRNA-124-5p correlated with poor prognosis in colorectal cancer via targeting of SMC4. Cancer Med. 3, 1544\u20131552 (2014).","journal-title":"Cancer Med."},{"key":"233_CR178","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.canlet.2014.09.005","volume":"355","author":"HY Wan","year":"2014","unstructured":"Wan, H. Y. et al. MiR-124 represses vasculogenic mimicry and cell motility by targeting amotL1 in cervical cancer cells. Cancer Lett. 355, 148\u2013158 (2014).","journal-title":"Cancer Lett."},{"key":"233_CR179","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/bjc.2012.537","volume":"108","author":"K Gebauer","year":"2013","unstructured":"Gebauer, K. et al. Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma. Br. J. Cancer 108, 131\u2013138 (2013).","journal-title":"Br. J. Cancer"},{"key":"233_CR180","doi-asserted-by":"publisher","first-page":"7017","DOI":"10.1007\/s13277-015-3369-3","volume":"36","author":"QZ Long","year":"2015","unstructured":"Long, Q. Z., Du, Y. F., Liu, X. G., Li, X. & He, D. L. miR-124 represses FZD5 to attenuate P-glycoprotein-mediated chemo-resistance in renal cell carcinoma. Tumour Biol. 36, 7017\u20137026 (2015).","journal-title":"Tumour Biol."},{"key":"233_CR181","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2490-9-6","volume":"9","author":"N Walsh","year":"2009","unstructured":"Walsh, N. et al. Expression of multidrug resistance markers ABCB1 (MDR-1\/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma. BMC Urol. 9, 6 (2009).","journal-title":"BMC Urol"},{"key":"233_CR182","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-303","volume":"12","author":"S Correa","year":"2012","unstructured":"Correa, S. et al. Wnt\/beta-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia. BMC Cancer 12, 303 (2012).","journal-title":"BMC Cancer"},{"key":"233_CR183","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/jcbfm.2014.100","volume":"34","author":"ML Pinzon-Daza","year":"2014","unstructured":"Pinzon-Daza, M. L. et al. The cross-talk between canonical and non-canonical Wnt-dependent pathways regulates P-glycoprotein expression in human blood-brain barrier cells. J. Cereb. Blood Flow Metab. 34, 1258\u20131269 (2014).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"233_CR184","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/0005-2736(76)90160-7","volume":"455","author":"RL Juliano","year":"1976","unstructured":"Juliano, R. L. & Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455, 152\u2013162 (1976).","journal-title":"Biochim. Biophys. Acta."},{"key":"233_CR185","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0014-5793(99)01744-5","volume":"465","author":"Y Nishii","year":"2000","unstructured":"Nishii, Y. et al. CROP\/Luc7A, a novel serine\/arginine-rich nuclear protein, isolated from cisplatin-resistant cell line. FEBS Lett. 465, 153\u2013156 (2000).","journal-title":"Febs Lett."},{"key":"233_CR186","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1016\/S0022-5347(05)65622-4","volume":"166","author":"S Hara","year":"2001","unstructured":"Hara, S., Miyake, H., Arakawa, S., Kamidono, S. & Hara, I. Over expression of inhibitor of caspase 3 activated deoxyribonuclease in human renal cell carcinoma cells enhances their resistance to cytotoxic chemotherapy in vivo. J. Urol. 166, 2491\u20132494 (2001).","journal-title":"J. Urol."},{"key":"233_CR187","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.canlet.2008.02.016","volume":"265","author":"PA Hueber","year":"2008","unstructured":"Hueber, P. A., Iglesias, D., Chu, L. L., Eccles, M. & Goodyer, P. In vivo validation of PAX2 as a target for renal cancer therapy. Cancer Lett. 265, 148\u2013155 (2008).","journal-title":"Cancer Lett."},{"key":"233_CR188","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1038\/sj.ki.5000136","volume":"69","author":"PA Hueber","year":"2006","unstructured":"Hueber, P. A., Waters, P., Clark, P., Eccles, M. & Goodyer, P. PAX2 inactivation enhances cisplatin-induced apoptosis in renal carcinoma cells. Kidney Int. 69, 1139\u20131145 (2006).","journal-title":"Kidney Int."},{"key":"233_CR189","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1093\/jjco\/hyv095","volume":"45","author":"N Ge","year":"2015","unstructured":"Ge, N. et al. Impact of O6-methylguanine-DNA methyltransferase expression on the drug resistance of clear cell renal cell carcinoma. Jpn J. Clin. Oncol. 45, 860\u2013866 (2015).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"233_CR190","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.3892\/mmr.2015.3740","volume":"12","author":"J Chen","year":"2015","unstructured":"Chen, J. et al. Low expression of phosphatase and tensin homolog in clearcell renal cell carcinoma contributes to chemoresistance through activating the Akt\/HDM2 signaling pathway. Mol. Med. Rep. 12, 2622\u20132628 (2015).","journal-title":"Mol. Med. Rep."},{"key":"233_CR191","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-6-16","volume":"6","author":"PY Lin","year":"2007","unstructured":"Lin, P. Y. et al. Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance. Mol. Cancer 6, 16 (2007).","journal-title":"Mol. Cancer"},{"key":"233_CR192","first-page":"773","volume":"2","author":"Y Fan","year":"2003","unstructured":"Fan, Y., Borowsky, A. D. & Weiss, R. H. An antisense oligodeoxynucleotide to p21(Waf1\/Cip1) causes apoptosis in human breast cancer cells. Mol. Cancer Ther. 2, 773\u2013782 (2003).","journal-title":"Mol. Cancer Ther."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41585-019-0233-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41585-019-0233-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41585-019-0233-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T20:40:00Z","timestamp":1721853600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-019-0233-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,10]]},"references-count":192,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["233"],"URL":"https:\/\/doi.org\/10.1038\/s41585-019-0233-z","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,10]]},"assertion":[{"value":"29 August 2019","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}